Platform based on innovative polymeric scaffolds applied as bio-absorbable implants
Initially being developed in breast cancer reconstruction and breast augmentation settings. Pivotal study for first indications recently announced involving leading breast cancer surgery centers in Italy and Spain.
Milan, Italy – January 30, 2025- Tensive S.r.l., an innovative biomedical company on a mission to offer breast cancer survivors a natural breast reconstruction and breast augmentation patients a superior clinical and aesthetic outcome has closed a €14,000,000 Series A financing led by Panakès Partners SGR. with participation from the EIC Fund, along with other institutional and angel investors. In conjunction with this investment Sanjay Kakkar, MD, MSc, MPH has joined the company as CEO.
“We are delighted to welcome Panakès as the lead investor along with the EIC, CDP, Recomec and other investors, and we appreciate the trust they have demonstrated in our vision and capabilities. The addition of Sanjay Kakkar to the team is a significant step forward as he brings a wealth of experience in the development of life sciences companies which will be instrumental in propelling Tensive toward its goals,” said Alberto Cantaluppi, MD, Chief Medical Officer, and co-Founder.
“We are excited to lead this Series A funding round for Tensive, whose innovation and vision are transforming the landscape of women’s health. Its groundbreaking technology has the power to make a profound difference in the lives of breast cancer survivors worldwide. It is a real privilege to support solutions that create lasting, meaningful impact for patients while also offering the potential for significant financial returns for investors. We look forward to collaborating closely with Tensive’s team as we embark on this journey of development, growth, and global expansion,” stated Diana Saraceni, Founder and Managing Partner at Panakès Partners.
“This financing round is a critical milestone towards realizing the potential of Tensive’s groundbreaking technology. The Series A funds will enable the company to complete a pivotal clinical trial evaluating the safety and performance of the company’s lead product, REGENERA, in patients undergoing reconstructive surgery after lumpectomy for malignant breast lesions,” stated Alessandro Tocchio, PhD, Chief Strategy Officer, and co-Founder. The company recently announced the initiation of the REGENERA pivotal study involving leading breast cancer surgery centers across Italy and Spain: Tensive S.r.l. Announces Multi-Center Pivotal Clinical Trial for REGENERA Implant in Post-Lumpectomy Breast Reconstruction | Tensive.
“This capital injection and valuable addition to the leadership team bring important resources and expertise that will be pivotal for Tensive’s growth. This vote of confidence from our existing and new investors is crucial for us to continue working towards our mission of improving the quality of life for breast cancer survivors by restoring their natural breast,” said Valentina Morigi, Chief Financial Officer, and co-Founder.
Sanjay Kakkar, MD, MSc, MPH (Chief Executive Officer) is a biotech and medtech entrepreneur with 30 years of experience in multinational, early-stage and high growth enterprises. He has a track record of building innovative companies in the life sciences industries in Europe, Asia and the US and advancing novel technologies for the improvement of human health. Prior to joining Tensive, he served as CEO at Tranquis (where he continues as Chairman), Peptilogics, Armetheon, and Trigen (which he also co-founded), and was the founder and chairman of Jai Medica. Before becoming a serial life sciences entrepreneur, he held R&D roles at Pharmacia (now Pfizer) and Novartis. Sanjay received his medical degree from King’s College, University of London, holds a master’s degree in healthcare management from Harvard University and a master’s degree in preventive cardiology from Imperial College. Sanjay was born and raised in the UK and has worked in the UK, Italy, Germany, India and the US.
“The unique properties of REGENERA hold incredible promise to bring forward a new class of bio-absorbable implants that potentially offer an easy-to-use, effective and practical option to manage breast disease following lumpectomy ultimately providing a natural breast shape and feel in a single-step, minimally invasive and potentially cost-saving procedure,” said Sanjay Kakkar, CEO. “I am genuinely excited to work closely with a group of groundbreaking innovators and leading investors to leverage this powerful technology to provide breast cancer survivors and healthcare practitioners an important new medical device to address a tremendous unmet clinical need.”
Tensive was advised by EY Advisory S.p.A. and Pavia e Ansaldo.
—
About Tensive S.r.l.
Tensive S.r.l. was founded in 2012 with the mission to offer breast cancer survivors the option for natural breast reconstruction after lumpectomy, and breast augmentation patients a superior aesthetic outcome through the development of proprietary, innovative bio-absorbable implants.
—
About Panakès Partners SGR
Panakès Partners is a Venture Capital firm, based in Milan, that invests in the most ambitious companies and teams developing revolutionary technologies and products in the field of life sciences with the aim of improving the lives of people around the world. Panakès, founded in 2016 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has €250 million under management.
—
About EIC Accelerator Program
The EIC Accelerator offers start-ups and SMEs grants of up to €2.5 million combined with equity investments through the EIC Fund ranging from €0.5 to €15 million. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading expertise, corporates, investors, and ecosystem actors.
—
For more information about Tensive: https://www.tensivemed.com
Media Relations: media@tensivemed.com